LinkedInXFacebook
Subscribe
Orthopedics This Week
  • My Feed
  • |Posts
  • |Events
  • |MSK Innovations
  • |Power Rankings
  • |Masterclasses
  • |Technology Awards
  • Press Releases
  • |Advertising
  • |Job Board
  • Spine
  • ◆Joints
  • ◆Upper Extremities
  • ◆Foot & Ankle
  • ◆Sports Medicine
  • ◆Pain Mgmt
  • ◆Trauma
  • ◆Biologics
  • ◆Technology
  • ◆People
  • ◆Company News
  • ◆Legal & Regulatory
Home/Spine/New PEEK Filament Announced for 3D Printed Implants
Spine

New PEEK Filament Announced for 3D Printed Implants

July 1, 2021 2 min read Premium comments

Advertisement

Secondary#evonik#3dprintablepeek#fusedfilamentfabrication

Evonik Industries AG, headquartered in Essen, Germany, has developed VESTAKEEP Care M40 3DF, a new 3D-printable PEEK (polyetheretherketone) biomaterial for medical applications which require body contact up to 30 days. The high-performance polymer can be processed in extrusion-based 3D printing technologies such as fused filament fabrication or fused deposition modeling.

VESTAKEEP Care M40 3DF, part of Evonik’s “Care Grade” line, features biocompatibility, excellent temperature and chemical resistance, very good sterilizability, and easy handling.

“Following the commercial success of our VESTAKEEP® i4 3DF filament for 3D printing long-term permanent implants, we are now expanding the possibilities of modern medical technology for the individual treatment of patients with this new Care product,” says Marc Knebel, head of the Medical Devices and Systems market segment at Evonik.

“This year we plan to launch an innovative PEEK-based filament with osteoconductive properties allowing bone cells to adhere to implants more quickly. Our goal is to revolutionize medical technology by offering innovative material solutions.”

OTW asked Knebel to describe how the high-performance polymer is both extrusion-based and 3D printed. Knebel explained, “The material in this process is a polymer filament that is supplied by a roll. A print head liquefies the material in a manner similar to a hot-melt glue gun. As a result, components are created layer by layer out of liquid polymer. A second print head adds support material, which it deposits into cavities and at overhangs, for example, because the component has to be supported in these areas during the printing process. This support material is removed after the component is finished.”

“VESTAKEEP Care M40 3DF is a filament extruded from natural colored, high viscosity VESTAKEEP Care M40 G PEEK. The material is designed for 3D printing of medical devices with up to 30 days body contact. The product impresses with its biocompatibility, excellent temperature and chemical resistance, very good sterilizability, and easy handling. The biocompatibility of the base resin has been tested following ISO 10993-1 recommendations for medical devices with up to 30 days of body contact and USP Class VI.”

“There is now a material available for short term contact applications such as surgical tools which can be in contact with the body for up to 30 days. With PEEK it is a material which can act as a metal replacement. The fused filament fabrication technology will help to bring ideas into a medical device with new design options which are outside of the possibilities of injection molding and machining. Parts can be designed in patient specific one-piece solutions up to midsize quantities of several hundreds.”

React:

Discussion

14
DS
Dr. Sarah MitchellOrthopedic Surgeon · Mayo Clinic

This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?

8
JT
James Thornton, MDSpine Fellow · HSS

Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.

5
RP
R. PatelSports Medicine · Stanford

We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.

Join the conversation

Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.

Subscribe

Get Full Access

Read every OTW article and join member discussions for $24.99/month.

Get Full Access

Advertisement

Advertisement

Advertisement

Orthopedics This Week

The most trusted source in orthopedic industry news since 2005. Covering spine, joints, trauma, biologics, and the business of orthopedics.

A publication of RRY Publications, LLC

LinkedInXFacebook

Categories

  • Spine
  • Joints
  • Upper Extremities
  • Foot & Ankle
  • Sports Medicine
  • Pain Mgmt
  • Trauma
  • Biologics
  • Technology
  • People
  • Company News
  • Legal & Regulatory

Resources

  • Subscribe
  • Community Posts
  • Job Board
  • Press Release Opportunities
  • Power Rankings
  • About OTW
  • Advertise
  • Contact Us

Get Full Access

Unlimited articles, community posts, and Power Rankings.

Get Full Access

Plans start at $24.99/mo · Annual saves 20%

© 2026 Orthopedics This Week · RRY Publications, LLC

Privacy PolicyTerms of ServiceCookie Policy